Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 wild-type |
| Therapy | Doxorubicin + GSK2830371 |
| Indication/Tumor Type | neuroblastoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 wild-type | neuroblastoma | predicted - sensitive | Doxorubicin + GSK2830371 | Preclinical | Actionable | In a preclinical study, GSK2830371 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463). | 25658463 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25658463) | WIP1 phosphatase as a potential therapeutic target in neuroblastoma. | Full reference... |